Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives
Eunus S. Ali
1
,
Shazid Md. Sharker
2
,
Muhammad Nazrul Islam
3
,
Ishaq Khan
4
,
Subrata Shaw
5
,
Atiqur Rahman
6
,
Jamal Uddin
7
,
Manik C. Shill
2
,
Shahnawaz Rehman
8
,
Niranjan Das
9
,
Saheem Ahmad
8
,
J.A Shilpi
7
,
Swati Tripathi
10
,
Siddhartha Mishra
11
,
Mohammad S. Mubarak
12
6
Division of Hematology and Oncology Mayo Clinic, Scottsdale, AZ, USA.
|
9
Department of Chemistry, Netaji Subhas Mahavidyalaya, Udaipur, Gomati Tripura, India
|
10
Publication type: Journal Article
Publication date: 2021-02-01
scimago Q1
wos Q1
SJR: 4.016
CiteScore: 35.0
Impact factor: 15.7
ISSN: 1044579X, 10963650
PubMed ID:
32014609
Cancer Research
Abstract
Nanotechnology is reshaping health care strategies and is expected to exert a tremendous impact in the coming years offering better healthcare facilities. It has led to not only therapeutic drug delivery feasibility but also to diagnostics. Materials in the size of nano range (1-100 nm) used in the design, fabrication, regulation, and application of therapeutic drugs or devices are classified as medical nanotechnology and nanopharmacology. Delivery of more complex molecules to the specific site of action as well as gene therapy has pushed forward the nanoparticle-based drug delivery to its maximum. Areas that benefit from nano-based drug delivery systems are cancer, diabetes, infectious diseases, neurodegenerative diseases, blood disorders and orthopedic-related ailments. Moreover, development of nanotherapeutics with multi-functionalities has a considerable potential to fill the gaps that exist in the present therapeutic domain. In cancer treatment, nanomedicines have superiority over current therapeutic practices as they can effectively deliver the drug to the affected tissues, thus reducing drug toxicities. Along this line, polymeric conjugates of asparaginase and polymeric micelles of paclitaxel have recently been recommended for the treatment of various types of cancers. Nanotechnology-based therapeutics and diagnostics provide greater effectiveness with less or no toxicity concerns. Similarly, diagnostic imaging holds promising future applications with newer nano-level imaging elements. Advancements in nanotechnology have emerged to a newer direction which use nanorobotics for various applications in healthcare. Accordingly, this review comprehensively highlights the potentialities of various nanocarriers and nanomedicines for multifaceted applications in diagnostics and drug delivery, especially the potentialities of polymeric nanoparticle, nanoemulsion, solid-lipid nanoparticle, nanostructured lipid carrier, self-micellizing anticancer lipids, dendrimer, nanocapsule and nanosponge-based therapeutic approaches in the field of cancer. Furthermore, this article summarizes the most recent literature pertaining to the use of nano-technology in the field of medicine, particularly in treating cancer patients.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
8
9
|
|
|
Pharmaceutics
9 publications, 4.15%
|
|
|
International Journal of Nanomedicine
6 publications, 2.76%
|
|
|
Cancers
5 publications, 2.3%
|
|
|
ACS Applied Bio Materials
5 publications, 2.3%
|
|
|
International Journal of Molecular Sciences
4 publications, 1.84%
|
|
|
Colloids and Surfaces B: Biointerfaces
4 publications, 1.84%
|
|
|
Small
4 publications, 1.84%
|
|
|
Nanomaterials
3 publications, 1.38%
|
|
|
ACS Omega
3 publications, 1.38%
|
|
|
Frontiers in Oncology
3 publications, 1.38%
|
|
|
Frontiers in Bioengineering and Biotechnology
3 publications, 1.38%
|
|
|
Inorganic Chemistry Communication
3 publications, 1.38%
|
|
|
Journal of Materials Chemistry B
3 publications, 1.38%
|
|
|
Biomaterials Science
3 publications, 1.38%
|
|
|
Journal of Drug Delivery Science and Technology
3 publications, 1.38%
|
|
|
Anti-Cancer Agents in Medicinal Chemistry
2 publications, 0.92%
|
|
|
Journal of Nanotheranostics
2 publications, 0.92%
|
|
|
Molecules
2 publications, 0.92%
|
|
|
Frontiers in Molecular Biosciences
2 publications, 0.92%
|
|
|
Journal of Hematology and Oncology
2 publications, 0.92%
|
|
|
Nano Today
2 publications, 0.92%
|
|
|
Cancer Letters
2 publications, 0.92%
|
|
|
Advances in Colloid and Interface Science
2 publications, 0.92%
|
|
|
Advanced Science
2 publications, 0.92%
|
|
|
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
2 publications, 0.92%
|
|
|
ACS applied materials & interfaces
2 publications, 0.92%
|
|
|
Materials Advances
2 publications, 0.92%
|
|
|
BMEMat
2 publications, 0.92%
|
|
|
International Journal of Biological Macromolecules
2 publications, 0.92%
|
|
|
1
2
3
4
5
6
7
8
9
|
Publishers
|
10
20
30
40
50
60
70
|
|
|
Elsevier
65 publications, 29.95%
|
|
|
MDPI
28 publications, 12.9%
|
|
|
Springer Nature
23 publications, 10.6%
|
|
|
Wiley
20 publications, 9.22%
|
|
|
American Chemical Society (ACS)
13 publications, 5.99%
|
|
|
Frontiers Media S.A.
13 publications, 5.99%
|
|
|
Royal Society of Chemistry (RSC)
13 publications, 5.99%
|
|
|
Taylor & Francis
11 publications, 5.07%
|
|
|
Bentham Science Publishers Ltd.
9 publications, 4.15%
|
|
|
IOP Publishing
3 publications, 1.38%
|
|
|
Pleiades Publishing
1 publication, 0.46%
|
|
|
Portland Press
1 publication, 0.46%
|
|
|
Neoplasia Press
1 publication, 0.46%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.46%
|
|
|
Hindawi Limited
1 publication, 0.46%
|
|
|
Baishideng Publishing Group
1 publication, 0.46%
|
|
|
World Scientific
1 publication, 0.46%
|
|
|
Korean Society of Environmental Risk Assessment and Health Science
1 publication, 0.46%
|
|
|
Moscow University Press
1 publication, 0.46%
|
|
|
AIP Publishing
1 publication, 0.46%
|
|
|
Allerton Press
1 publication, 0.46%
|
|
|
IGI Global
1 publication, 0.46%
|
|
|
EDP Sciences
1 publication, 0.46%
|
|
|
Tsinghua University Press
1 publication, 0.46%
|
|
|
American Society for Microbiology
1 publication, 0.46%
|
|
|
Emerald
1 publication, 0.46%
|
|
|
Spandidos Publications
1 publication, 0.46%
|
|
|
10
20
30
40
50
60
70
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
218
Total citations:
218
Citations from 2024:
103
(47.46%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Ali E. S. et al. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives // Seminars in Cancer Biology. 2021. Vol. 69. pp. 52-68.
GOST all authors (up to 50)
Copy
Ali E. S., Sharker S. M., Islam M. N., Khan I., Shaw S., Rahman A., Uddin J., Shill M. C., Rehman S., Das N., Ahmad S., Shilpi J., Tripathi S., Mishra S., Mubarak M. S. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives // Seminars in Cancer Biology. 2021. Vol. 69. pp. 52-68.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.semcancer.2020.01.011
UR - https://doi.org/10.1016/j.semcancer.2020.01.011
TI - Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives
T2 - Seminars in Cancer Biology
AU - Ali, Eunus S.
AU - Sharker, Shazid Md.
AU - Islam, Muhammad Nazrul
AU - Khan, Ishaq
AU - Shaw, Subrata
AU - Rahman, Atiqur
AU - Uddin, Jamal
AU - Shill, Manik C.
AU - Rehman, Shahnawaz
AU - Das, Niranjan
AU - Ahmad, Saheem
AU - Shilpi, J.A
AU - Tripathi, Swati
AU - Mishra, Siddhartha
AU - Mubarak, Mohammad S.
PY - 2021
DA - 2021/02/01
PB - Elsevier
SP - 52-68
VL - 69
PMID - 32014609
SN - 1044-579X
SN - 1096-3650
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Ali,
author = {Eunus S. Ali and Shazid Md. Sharker and Muhammad Nazrul Islam and Ishaq Khan and Subrata Shaw and Atiqur Rahman and Jamal Uddin and Manik C. Shill and Shahnawaz Rehman and Niranjan Das and Saheem Ahmad and J.A Shilpi and Swati Tripathi and Siddhartha Mishra and Mohammad S. Mubarak},
title = {Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives},
journal = {Seminars in Cancer Biology},
year = {2021},
volume = {69},
publisher = {Elsevier},
month = {feb},
url = {https://doi.org/10.1016/j.semcancer.2020.01.011},
pages = {52--68},
doi = {10.1016/j.semcancer.2020.01.011}
}